Clinical Trial: Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)

U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT07535489) titled 'Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)' on April 10.

Brief Summary: This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and pharmacokinetics of IPG11406, an investigational oral drug, in adult patients with moderately to severely active ulcerative colitis (UC).

UC is a chronic inflammatory bowel disease that causes long-term inflammation and ulcers in the colon, leading to symptoms like frequent diarrhea, rectal bleeding, abdominal pain, and urgent bowel movements. IPG11406 works by targeting the GPR183 receptor,...